Loading...
Market
How many hospitals will adopt the AI-based gBRCA pre-screening tool by December 31, 2025?
2
Resolution / Starting Odds
0-10 • 25%
11-50 • 25%
51-100 • 25%
101+ • 25%
Official announcements from hospitals, Owkin, or AstraZeneca
Story
Owkin and AstraZeneca Partner to Develop AI-Based gBRCA Breast Cancer Pre-Screening Tool
Oct 2, 2024, 02:17 PM
Owkin has announced a new partnership with AstraZeneca to develop an AI-powered pre-screening solution for gBRCA mutations (gBRCAm) in breast cancer. This tool aims to simplify genetic testing by analyzing digitized pathology slides to identify BRCA1 and BRCA2 mutations. The initiative seeks to accelerate and expand access to gBRCA testing, which many patients may not currently receive. The partnership was announced on October 2, 2024.
View original story
Similar markets
0-10 • 25%
11-50 • 25%
51-100 • 25%
More than 100 • 25%
0-10 providers • 25%
11-20 providers • 25%
21-30 providers • 25%
More than 30 providers • 25%
0-10 • 25%
11-50 • 25%
51-100 • 25%
More than 100 • 25%
Yes • 50%
No • 50%
1-2 hospitals • 25%
3-4 hospitals • 25%
5-6 hospitals • 25%
More than 6 hospitals • 25%
0-4 • 25%
5-9 • 25%
10-14 • 25%
15 or more • 25%
Yes • 50%
No • 50%
0-10 hospitals • 33%
11-20 hospitals • 33%
21+ hospitals • 34%
Yes • 50%
No • 50%
